Logo image
Back
Aggressive relapsing multiple sclerosis characterized by rapid disability progression
Journal article

Aggressive relapsing multiple sclerosis characterized by rapid disability progression

Thomas F. Scott, Genevieve Laforet and Xiaojun You
Multiple sclerosis and related disorders, v 2(4), pp 370-376
01 Oct 2013
DOI: https://doi.org/10.1016/j.msard.2013.03.006
PMID: 25877848
Featured in Collection :   UN Sustainable Development Goals @ Drexel

Abstract

Clinical Neurology Life Sciences & Biomedicine Neurosciences & Neurology Science & Technology
Background: Criteria for identifying relapsing multiple sclerosis (RMS) patients with aggressive disease, which would be useful for clinical decision making, are currently unavailable. Objective: Identify RMS patients with aggressive disease characterized by rapid disability progression. Methods: Data from a 2-year, phase 3, double-blind, placebo-controlled trial with long-term follow-up evaluations of RMS patients taking either intramuscular interferon beta-1a (IM IFN beta-1a, 30 mu g) or placebo with baseline Expanded Disability Status Scale (EDSS) scores of 1.0-3.5 were retrospectively analyzed. Patients with a >= 2.0-point increase in EDSS score, resulting in a score >= 4.0 by study end, were considered to have aggressive RMS. The risk of a poor long-term outcome, defined as an EDSS score >= 8.0 at 8 years of follow-up, was calculated as an odds ratio from a logistic regression model comparing patients with and without aggressive RMS. Results: Only 25 patients met the criteria for aggressive RMS. Among these patients, mean disease duration was 5.1 +/- 3.85 years, mean baseline age was 37.2 +/- 6.35 years, and mean baseline EDSS score was 2.8 +/- 0.74. Fewer IM IFN beta-1a-treated than placebo-treated patients met the criteria for aggressive RMS at 2 years (7% vs 22% on placebo, p=0.0072). Thirteen patients reached the EDSS milestone of >= 8.0 by the end of the 8-year follow-up. The odds ratio for attaining severe disability was 86.4 (95% CI, 10.3-726.4; p<0.0001) for patients with aggressive RMS compared to patients without aggressive RMS. Conclusions: Defining aggressive RMS based on rapid EDSS progression was useful in identifying patients at risk for more severe disease course. (C) 2013 Elsevier B.V. All rights reserved.

Metrics

1 Record Views
4 citations in Web of Science
4 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Industry collaboration
Domestic collaboration
Web of Science research areas
Clinical Neurology
Logo image